mdlinx mdlinx

MDLinx E-mail Article

To email this article, enter your own "From Email" address, the recipient's "To Email" address, and click the "Send Email" button. You may send to up to 5 emails at a time.


* From Email: 
* To Email: 
To Email: 
To Email: 
To Email: 
To Email: 
Email Subject Line: 
Comments:

Paediatric follow-up of haemodynamically insignificant congenital cardiac lesions

Smith BG et al. – The increasingly sensitive and advanced nature of echocardiography and the subsequent reliance upon it may be contributing to unnecessarily frequent review of haemodynamically insignificant congenital cardiac lesions (HICCL) and a reluctance to discharge patients. In the majority of patients with HICCL, no more than two assessments of HICCL are required after 2 years of age – once in late childhood and once near full growth.

Methods
  • An internet-based survey of 170 paediatric cardiologists and general paediatricians with an interest in cardiology in the UK.
  • Five scenarios concerning common HICCL were presented: ventricular and atrial septal defects, patent foramen ovale, mild pulmonary stenosis and persistent ductus arteriosus.

Results
  • There were 52 respondents.
  • There was a broad range of beliefs and practices. However, there were tendencies to discharge children with a patent foramen ovale and follow patients with all other lesions, often on a relatively frequent basis.
[more...]

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close